Coronavirus and a New Member of This Family (COVID-19) - What You Need to Know

Why Should You Attend:

Coronavirus is considered a threat to the entire human life due to the lack of a sufficient preventive and treatment strategy to protect against it until now. This webinar explains scientific content in simple terms to rule out the confusion caused by the humongous amount of information circulating online about this Pandemic.

The Coronaviruses (CoV) are positive sense RNA viruses possessing spike-like projections on the surface creating a crown-like appearance upon magnification with electron microscopy. They are a large family of viruses causing a wide range of illness from the common cold to more severe diseases, such as Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV).

The novel coronavirus (2019-nCoV) or the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a man-made chimera that was engineered in 2015 in the University of North Carolina at Chapel Hill.

This engineered virus claimed its first victim in the Wuhan Institute of Virology, in Wuhan China in December 2019. On December 31st 2019, China notified the outbreak to the World Health Organization. The World Health Organization (WHO) on March 11, 2020, declared COVID-19 a pandemic, pointing to the over 118,000 cases of the coronavirus illness in over 110 countries and territories around the world and the sustained risk of further global spread.

Learning Objectives:

• Following the completion of this webinar you will gain a basic to moderate knowledge of Corona viruses in general and COVID-19, its biology, transmission, epidemiology, clinical features, warning signs, diagnosis, risk factors, and prevention of COVID-19.
• Countermeasures will be discussed at a high level and will be broken down into potential treatments that block the viral lifecycle (monoclonal antibodies, Camostat mesylate, chloroquine/hydroxychloroquine, lopinavir-ritonavir, remdesivir); potential anti-inflammatories (corticosteroids and baricitinib); immune boosters; and potential vaccines.

Areas Covered in the Webinar:

• Emergence of COVID-19
• Comparison with other strains of Coronoviruses
• Biology and life-cycle
• Epidemiology and pathogenesis
• Transmission
• Incubation period
• Clinical features
• Warning signs
• Diagnosis
• Differential diagnosis
• Prevention
• Risk factors
• Therapeutic recommendations
• An over view of the potential treatment candidates

Who Will Benefit:

• Anyone who has concerns about the COVID-19 pandemic and wants to understand more about the scientific basis for how it came about, what it is, what we are doing to combat it and what to expect in the future.
• Professionals from any industry or company of any size.

Dr. Afsaneh Motamed Khorasani
Vice President of Medical Affairs, Easy Global Training

Dr. Afsaneh Motamed Khorasani, PhD, is a Medical and scientific Affairs expert and a Senior Scientist with a strong background in biomedical science and clinical trial/research. She has a tenured and diverse range of experience in medical affairs, basic and industrial clinical research and development, clinical trials, Medical and regulatory writing and intellectual property. She is currently the Vice President of Medical Affairs at Easy Global Training, which is a US-based firm providing global regulatory, quality and medical affairs training backed by consulting. Before joining this company, Dr. Motamed Khorasani has served as an independent consultant, director of medical affairs, senior medical sciences liaison, senior scientist and senior medical analyst at Merck (MDS), Johnson & Johnson, United States Pharmacopeia Convention (USP), Amgen, Baxter International, Covidien (eV3), Radient Pharmaceuticals, AMDL Diagnostics, Microbix Biosystems, Neometrix Consulting, Mount Sinai Hospital, Princess Margaret Hospital, and Vancouver General Hospital.

She has more than 20 years of experience and many National and international certificates in GLP, GMP, ICH-GCP and global regulatory compliance for clinical trials and is a member in a number of professional associations, including: American Association of Cancer Research (AACR), American Medical Writers Association (AMWA), Regulatory Affairs Professional Society (RAPS), American Society of Quality (ASQ), Project Management Institute (PMI), and Intellectual Property Institute of Canada (IPIC). Dr. Motamed Khorasani's research has focused on high throughput approaches in the context of cancer informatics with a particular interest in the use of comparative analysis for the mining of integrated oncology datasets that include protein-protein interaction and gene expression profiling. She has published and presented more than 50 papers, abstracts and articles in highly regarded scientific journals and high profile conferences and scientific meetings.

Follow us :